Market News & Trends
Baxalta & Momenta Announce Initiation of Pivotal Clinical Trial for Biosimilar
Baxalta Incorporated and Momenta Pharmaceuticals, Inc. recently announced the initiation of a pivotal clinical trial in patients with chronic plaque psoriasis for M923, a biosimilar…
Merck Millipore Adds Protein Pegylation to Portfolio of Services Through Collaboration
Merck Millipore recently announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled…
Hemispherx Biopharma Receives New Composition of Matter Patent
Hemispherx Biopharma, Inc. recently announced it received formal notice on September 21, 2015, that the European Patent Office's Examining Division granted the Company's application titled…
Cellectar Biosciences Announces Pricing of $3.3 Million Financing
Cellectar Biosciences, Inc. recently announced the pricing of a registered direct offering of 1,017,272 shares of its common stock and Series B pre-funded warrants to…
AAA Announces Positive Results From Phase III Study
Advanced Accelerator Applications S.A. recently announced that the pivotal Phase III NETTER-1 study for Lutathera (177Lu-DOTATATE) met its primary endpoint of assessing progression-free survival (PFS),…
Bayer Receives FDA Approval for First & Only Electronic Autoinjector in RRMS Treatment
Bayer HealthCare recently announced the US FDA approved BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). BETACONNECT will…
Genisphere Closes $4 Million for Expansion of 3DNA Targeted Drug Delivery Platform
Genisphere LLC recently announced it has closed a $4-million equity round. This round of fundraising will extend and expand development of Genisphere's targeted drug delivery…
PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need
PharmaCyte Biotech, Inc. recently announced the second in a series of articles that will serve to educate the public on its technology and how it…
Vetter Embarks on a 300 Million Euro Investment Strategy
Ravensburg, Germany, September 30, 2015 – Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug…
Ultra-Low Flow Technology for Drug Delivery
FARMINGTON, CT (September 2015) – Mott Corporation has developed a technology that controls the flow rate of a liquid or drug in devices over…
Scholar Rock Presents First Data, Announces Lead Drug Program
Scholar Rock recently announced that SRK-015 is the company’s lead drug development candidate, a niche modulator inhibiting activation of the latent myostatin precursor. The announcement…
RegeneRx Announces First Patient Enrolled in Phase III Trial
RegeneRx Biopharmaceuticals, Inc. recently announced the first patient has been enrolled in a Phase III clinical trial with RGN-259 (designated GBT-201 in Korea), its sterile,…
Deciphera Pharmaceuticals Announces $75-Million Financing
Deciphera Pharmaceuticals recently announced it has closed a $75-million Series B financing led by New Leaf Venture Partners and joined by Deciphera’s existing investors. The…
BIND Therapeutics Announces Pfizer Exercises Option
BIND Therapeutics, Inc. recently announced Pfizer Inc. exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the…
Xcelience & Powdersize Add Delta Vita Nano-Milling
Xcelience and Powdersize recently announced the addition of the Netzsch Delta Vitamedia mills, a nanoparticle milling solution, to their arsenal of capabilities. For the first…
Nemera’s Next-Generation Nasal Spray Now in Production
Nemera has invested more than 10 million euros in R&D and manufacturing to launch the only user-independent multi-dose nasal spray system on the market. So…
Oncology Leads Development in Promising Gene Therapy Pipeline
Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with 906 products in active development…
EMD Millipore Introduces Enhancements to its EMPROVE® Program
EMD Millipore Introduces Enhancements to its EMPROVE® Program EMD Millipore recently introduced enhancements to its industry-leading EMPROVE portfolio of pharmaceutical raw materials. The expanded documentation…
Drug Development & Delivery to Launch Innovation Networking Event
Drug Development & Delivery President & Publisher Ralph Vitaro recently announced that the leading media company will be hosting the inaugural Innovation Networking Summit &…
Dimension Therapeutics Announces FDA Fast Track Designation
Dimension Therapeutics, Inc. recently announced that the US FDA has granted Fast Track designation for the company’s lead product candidate, DTX101, for the treatment of…
